TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Real-time Urodynamic Measure of Urinary Urgency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have symptoms of urge or mixed incontinence (urge predominant) and desire treatment with anticholinergic medication.~* Demonstrated detrusor overactivity with or without incontinence during urodynamic testing.~* Are able to consent and fill out study documents, complete repeated urodynamic testing, and follow-up in 4 weeks.~Exclusion Criteria:~* Have been treated with any anticholinergic medication in the previous month.~* Have an elevated post -void residual volume as determined during their routine clinical care.~* Have had a urinary tract infection in the last month, as determined by history.~* Have untreated narrow angle glaucoma, by patient history.~* Have a known allergy or intolerance to solifenacin, as determined by patient history.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solifenacin Succinate (Type: EXPERIMENTAL): The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria~* Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints~* Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)~* Men must agree to use a reliable method of birth control or remain abstinent during the study~* Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs)~Exclusion Criteria:~* Current or prior use of biologic agents for treatment of Ps or PsA~* Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDS)~* Current use of more than one cDMARDs~* Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA~* Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy~* Serious disorder or illness other than psoriatic arthritis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab Open Label (Type: EXPERIMENTAL): Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
- Ixekizumab (Type: EXPERIMENTAL): Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse).
- Placebo (Type: PLACEBO_COMPARATOR): Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)
- IXE80Q2W Non-randomized (Type: EXPERIMENTAL): Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 40-85 years old~* With or without Parkinson's disease~* Experiencing RBD episodes on average at least 2x/week or 8x/month~* Able to report RBD episodes themselves or via a partner witness~Exclusion Criteria:~* History of falls during ambulation in the last 6 months despite adequate neurologic treatment~* Requirement of an ambulatory device at home~* Inadequately treated symptomatic orthostatic hypotension~* BMI \> 35~* Untreated or uncontrolled OSA (4%AHI\>15)~* Cognitive impairment resulting in inability to comply with treatment instructions~* Pregnancy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Oxybate (SXB) arm (Type: ACTIVE_COMPARATOR): Sodium Oxybate (SXB) will be dispensed to the participants.
- Placebo (PBO) arm (Type: PLACEBO_COMPARATOR): Placebo will be dispensed to the participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A patient with an IOP greater than or equal to 20 mmHg related to unilateral or bilateral OH or OAG (primary open angle glaucoma, pseudo-exfoliative glaucoma, and pigmentary glaucoma), after a visual field exam~* Naive patients (i.e. never having been treated) and requiring treatment initiation~Exclusion Criteria:~* A patient with OH or OAG currently on treatment~* A patient with OH or OAG previously treated (regardless of the date treatment was discontinued)~* A patient with traumatic, inflammatory, or neovascular glaucoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Latanoprost group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Maintenance Medications Comparison Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion~* age 21 to 55 years~* diagnosis of opioid dependence by criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)~* evidence of recent opioid use on toxicologic screening~Exclusion~* serious medical or psychiatric illness requiring long-term medication~* positive pregnancy test

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does a Single Shot Femoral Nerve Block Alone Produce Appropriate Pain Relief?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* Undergoing two TKA~* Understanding PCA protocol~Exclusion Criteria:~* Skin infection near injection site~* Allergy to local analgesics~* Peripheral neuropathy~* Coagulopathy~* Dementia~* Proven opioid dependency

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Femoral Nerve Block (Type: ACTIVE_COMPARATOR): None
- Combined Nerve Blocks (Type: ACTIVE_COMPARATOR): None
- Patient-controlled analgesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed endometrial hyperplasia,~* D-score \> 0,~* Age 30-70 years,~* No contra-indications against progestin hormones,~* Written consent,~* Patients who have been treated with transcervical resection need a histologically confirmed diagnosis of hyperplasia taken after the TCR~Exclusion Criteria:~* D-score \< 0,~* Age \< 30 or \> 70,~* Increased sensitivity to progestins,~* Pregnancy,~* Infection or cancer in genitalia or mammary gland,~* Liver disease,~* Serious thrombophlebitis.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MPA 10 mg per oral cyclic for 6 months (Type: ACTIVE_COMPARATOR): The peroral treatment is used 10 days each month
- MPA 10 mg per os continuous 6 months (Type: ACTIVE_COMPARATOR): Per oral MPA 10 mg is taken daily for 6 months
- LNG-IUD for 6 months (Type: ACTIVE_COMPARATOR): Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of peri-implant mucositis~* at least one implant~* probing depth (PD) ≤5mm~* BOP (bleeding on probing)~* No radiographic evidence of bone loss beyond the first two threads of the implant~Exclusion Criteria:~* Active Periodontitis or Peri-implantitis which requires definitive treatment.~* Presence of oral local mechanical factors that could (in the opinion of the PI) influence the outcome of the study.~* Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed.~* Presence of soft or hard tissue tumors of the oral cavity.~* Patients treated with systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 12 weeks prior to study entry and throughout the study duration.~* Patients chronically (i.e. two weeks or more) treated with non-steroidal anti-inflammatory drugs (NSAIDs) or any medications know to affect soft tissue condition (excluding treatment of Acetylsalicylic acid ≤ 100 mg/day).~* Patients with uncontrolled diabetes, of any type, and/or patients with HbA1c test value \>7.5% dated 3 months prior to the screening visit.~* Patients receiving radiation therapy to the head and neck area and/or receiving immunosuppressive therapy.~* The presence of any medical or psychiatric condition or any other condition that, in the opinion of the Investigator, could affect the successful participation of the patient in the study.~* Drug and alcohol abuse.~* Patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.~* Subject is pregnant (based on pregnancy result) or lactating.~* Subject is a smoker, or has been a smoker within the past 6 months.~* Any other condition that may interfere with the study as judged by the PI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Test - stabilized chlorine dioxide rinse (Type: EXPERIMENTAL): Subjects will receive CloSYS Ultra Sensitive Rinse
- Placebo - oral rinse, no active ingredients (Type: PLACEBO_COMPARATOR): Subjects will receive oral rinse - no active ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18-100 years of age with suspected, mild, moderate, or severe glaucoma~Exclusion Criteria:~* Non-English speakers, patients with systemic or ocular disease affecting central vision, best corrected visual acuity less than 20/80, neurocognitive or psychiatric disorders that would confound visual field testing, those with physical inability to perform testing, and astigmatism with absolute values greater than 2.00 diopters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Group A: HFA followed by SSVR (Type: OTHER): Patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized. Group A includes participants who tested using the HFA, followed by a 15 minute rest period, then tested with the SSVR.
- Group B: SSVR followed by HFA (Type: OTHER): Patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with both the Humphrey HFA-III perimeter and the SmartSystem VR headset on the same clinic visit, spaced roughly 10-15 minutes apart. The sequence in which each patient undertakes the two tests will be randomized. Group B includes participants who tested using the SSVR, followed by a 15 minute rest period, then tested with the HFA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose conditions are defined as definite ALSor probable ALSdiagnostic criteria El Escorial and revised Airlie House.~* Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.~* Patients of less than 2 years after the onset of ALS.~* Patients whose progress of the condition during 12 weeks before administration meet other requirements.~Exclusion Criteria:~* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.~* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.~* Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.~* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women requesting contraception with Kyleena. The woman's informed decision for contraception with Kyleena was made before and independently from the study as per investigator's routine practice~* Written informed consent.~Exclusion Criteria:~* Contraindications for Kyleena according to the local market authorization/SmPC~* Mental incapacity to consent and provide data during the observational study~* Women participating in an investigational program with interventions outside of routine clinical practice.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Kyleena (Type: None): Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients at least 18 years of age~* Diagnosis of PsA classified by CASPAR criteria and with symptoms for at least 6 months with moderate to severe PsA who must have at Baseline ≥3 tender joints out of 78 and ≥3 swollen out of 76 (dactylitis of a digit counts as one joint each)~* Rheumatoid factor and/or anti-CCP antibodies negative at screening~* A target skin psoriatic lesion and a PASI score of 1 or greater~Exclusion Criteria:~* Chest X-ray with evidence of ongoing infectious or malignant process~* Patients who ever received biologic immunomodulating agents including those targeting TNFα, IL-6 and IL-12/23 investigational or approved

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): secukinumab 300mg s.c. injection
- Group 2 (Type: ACTIVE_COMPARATOR): secukinumab 150 mg s.c. injection
- Group 3 (Type: PLACEBO_COMPARATOR): Placebo s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of either sex aged 21 years or more, in sinus rhythm for at least 1 hour at the time of randomisation and with at least one ECG-documented AF/AFL episode in the last 3 months.~Exclusion Criteria:~* MAIN CRITERIA (non-exhaustive list, see protocol for details):~Women of childbearing potential without adequate birth control, Pregnant women, Breastfeeding women, Congestive heart failure NYHA class III or IV, Conditions which increase the risk of severe antiarrhythmic drug side effects, Severe associated conditions.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dronedarone 400mg bid (Type: EXPERIMENTAL): dronedarone 400mg tablets
- Placebo (Type: EXPERIMENTAL): matching placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete